Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Publication number: 20110171222Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 17, 2010Publication date: July 14, 2011Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
-
Publication number: 20110171221Abstract: Compositions and methods for the diagnosis, treatment and prevention of cancer, including prostate cancer and renal cell carcinoma, as well as for treatment selection.Type: ApplicationFiled: October 8, 2010Publication date: July 14, 2011Applicant: University of Florida Research FoundationInventors: Johannes Vieweg, Zhen Su, Dennis A. Steindler
-
Publication number: 20110171125Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: March 31, 2010Publication date: July 14, 2011Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
-
Patent number: 7977462Abstract: The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: GrantFiled: April 18, 2008Date of Patent: July 12, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Peter Hornbeck, Ailan Guo, Ting-Lei Gu, Klarisa Rikova, Albrecht Moritz, Charles Farnsworth, Matthew Stokes, Jian Yu, Erik Spek, Yu Li, Anthony Possemato, Jessica Cherry, Valerie Goss, Jeffrey Mitchell, John Rush, Corinne Michaud
-
Publication number: 20110165153Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: ApplicationFiled: September 17, 2010Publication date: July 7, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
-
Publication number: 20110165062Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or inhibiting its metastasis-promoting activity, said antibodies consisting of antibodies secreted by the hybridoma deposited at the ATCC under number CRL-2696.Type: ApplicationFiled: April 2, 2009Publication date: July 7, 2011Applicant: PIERRE FABRE MEDICAMENTInventor: Jean-Francois Haeuw
-
Publication number: 20110165161Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to epithelial cell adhesion/activating molecule EpCAM expressed on cancer cells and induce cancer cell apoptosis. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: ApplicationFiled: December 23, 2010Publication date: July 7, 2011Inventors: Shih-Yao LIN, Leewen Lin, Feng-Lin Chiang, Shu-Hua Lee, Yu-Ying Tsai
-
Publication number: 20110158988Abstract: The present invention relates to an affinity ligand capable of selective interaction with a subset consisting of 37 consecutive amino acid residues or less from extracellular domains 2 and 3 of HER2, wherein the subset comprises the amino acid sequence LQVF and/or ESFDGD1 and to polypeptides consisting of such subsets.Type: ApplicationFiled: December 12, 2008Publication date: June 30, 2011Applicant: ATLAS THERAPEUTICS ABInventors: Mathias Uhlen, Johan Rockberg
-
Publication number: 20110160288Abstract: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody. The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.Type: ApplicationFiled: August 24, 2009Publication date: June 30, 2011Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Akira Togashi
-
Publication number: 20110150759Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: August 14, 2008Publication date: June 23, 2011Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephan Stockert, Lioyd J. Old
-
Publication number: 20110150876Abstract: The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided.Type: ApplicationFiled: January 20, 2011Publication date: June 23, 2011Applicant: Trustees of Dartmouth CollegeInventor: William B. Kinlaw, III
-
Publication number: 20110142840Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.Type: ApplicationFiled: May 21, 2009Publication date: June 16, 2011Inventors: Edward Thein Htun Van Der Horst, Aaron Ken Sato
-
Patent number: 7959915Abstract: The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.Type: GrantFiled: September 12, 2005Date of Patent: June 14, 2011Assignee: Tufts UniversityInventors: Daniel G. Jay, Brenda K. Eustace, Takashi Sakurai
-
Patent number: 7956164Abstract: T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.Type: GrantFiled: January 14, 2010Date of Patent: June 7, 2011Assignee: Immunovative Therapies Ltd.Inventor: Michael Har-Noy
-
Publication number: 20110129464Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.Type: ApplicationFiled: December 16, 2010Publication date: June 2, 2011Inventors: CAMELLIA W. ADAMS, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7951370Abstract: The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides for methods of modulating activity of TYRP1, treating growth of a cancer cell, and treating a malignant melanoma in mammals by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment.Type: GrantFiled: March 11, 2009Date of Patent: May 31, 2011Assignee: ImClone LLCInventors: Paul J. Balderes, Xiaoqiang Kang
-
Patent number: 7947459Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high'degree of structural conservation among them but show no significant structural homology to any known human proteins. STEAP-2 is a 454 amino acid protein characterized by a predicted molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: January 6, 2004Date of Patent: May 24, 2011Assignee: Agensys, Inc.Inventors: Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Patent number: 7939077Abstract: The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.Type: GrantFiled: June 28, 2002Date of Patent: May 10, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Kazuyasu Nakamura, Maiko Hirota, Naoki Shimada
-
Publication number: 20110104148Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 31, 2010Publication date: May 5, 2011Applicant: Roche GlycArt AGInventors: Ekkehard MÖSSNER, Thomas U. HOFER, Ralf Jörg HOSSE, Pablo UMAÑA
-
Patent number: 7935791Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.Type: GrantFiled: December 17, 2007Date of Patent: May 3, 2011Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
-
Patent number: 7932229Abstract: The present invention provides new methods and uses of peptides in effecting a reduction in mammary cell number. The discovery that these peptides reduce mammary cell number further enables the use of these peptides in the treatment of cancer where the peptides can be used to reduce cell number and accordingly reduce or prevent tumour development. The inventor has further shown that the peptides have specific utility in the treatment of breast cancer.Type: GrantFiled: October 21, 2005Date of Patent: April 26, 2011Assignee: AvantiCell Science LtdInventor: Colin James Wilde
-
Patent number: 7928071Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: July 24, 2006Date of Patent: April 19, 2011Assignees: Yale Universtiy, Imperial Cancer Research Foundation, Ltd.Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
-
Patent number: 7928202Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.Type: GrantFiled: April 11, 2008Date of Patent: April 19, 2011Assignee: The Brigham and Women's Hospital, Inc.Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
-
Patent number: 7923212Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: November 23, 2009Date of Patent: April 12, 2011Assignee: ZymoGenetics, Inc.Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
-
Patent number: 7915000Abstract: Small animal models for assessing immunomodulatory effects of compounds are provided.Type: GrantFiled: November 13, 2007Date of Patent: March 29, 2011Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Anke Kretz-Rommel
-
Patent number: 7915390Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.Type: GrantFiled: October 18, 2007Date of Patent: March 29, 2011Assignee: Genentech, Inc.Inventors: Kang Li, Bin-Bing Stephen Zhou, Wenjuan Wu, Sek Chung Fung, Sanjaya Singh
-
Patent number: 7910704Abstract: Novel human p53 splice variant displaying differential transcriptional activity Described is a nucleic acid molecule encoding a p53 variant characterized in that it is capable of transactivating the p21- and 14-3-3?-promoter but not the mdm2-, bax- and PIG3-promoter. Preferably, in said p53 variant exon 7, exon 8 and/or exon 9 are partially or entirely deleted. Finally, means for inhibiting the activity of this p53 variant are described which are useful for the therapy of cancer.Type: GrantFiled: September 27, 2005Date of Patent: March 22, 2011Inventors: Wolfgang W. Deppert, Irene Dornreiter
-
Publication number: 20110064739Abstract: The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e. cell cycle and apoptosis, cell growth, extracellular signaling, angiogenesis and invasion, is identified, whose expression is significantly changed. In particular, the expression pattern found uncovers the network of molecules leading to mammalian papillary adenocarcinomas of the lung.Type: ApplicationFiled: September 27, 2010Publication date: March 17, 2011Inventors: JÜRGEN BORLAK, TATJANA MEIER, ROMAN HALTER
-
Publication number: 20110059091Abstract: Isoform-binding molecules that specifically bind to one or more isoforms expressed and/or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding molecules can be used to treat, prevent and/or diagnose cancerous conditions and/or disorders. Methods of using the isoform-binding molecules to selectively detect oncogenic isoforms, to reduce the activity and/or induce the killing of a hyperproliferative cell expressing an oncogenic isoform in vitro, ex vivo or in vivo are also disclosed. Diagnostic and/or screening methods and kits for evaluating the function or expression of an oncogenic isoform are also disclosed.Type: ApplicationFiled: February 4, 2009Publication date: March 10, 2011Inventors: Xiao-Jia Chang, Ullrich S. Schwertschlag
-
Publication number: 20110059090Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: November 27, 2008Publication date: March 10, 2011Applicant: Ablynx N.V.Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Patent number: 7902338Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a the substitution of serine for phenylalanine at Kabat residue 91 in the human framework region in the hA19 VH sequence.Type: GrantFiled: November 7, 2008Date of Patent: March 8, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7902339Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.Type: GrantFiled: July 21, 2006Date of Patent: March 8, 2011Assignee: University of MassachusettsInventors: Kenneth L. Rock, Dancella Fernandes
-
Patent number: 7897730Abstract: This invention relates generally to the preparation of TRAIL receptor-binding agents and uses of the same. In particular, the present invention relates to the preparation of anti-TRAIL receptor antibodies which recognize a common antigen determinant (i.e., epitope) shared by TRAIL-R1 and TRAIL-R2 receptors and their use for TRAIL receptor detection and modulation of TRAIL receptor-mediated function. The TRAIL receptor-binding agents are useful to induce apoptosis in human cancer cells. These targets may either express one or both TRAIL-R1 or TRAIL-R2. The invention provides for the use of the TRAIL receptor-binding agents of the invention in cancer therapy.Type: GrantFiled: April 29, 2007Date of Patent: March 1, 2011Assignee: Beijing Cotimes Biotech Ltd.Inventors: Zheng Yu, Min Zhou, Enyun Shen, Xianzhao Jia, Yang Song
-
Publication number: 20110045495Abstract: The present invention relates to a method for detection of a renal cancer, comprising measuring any one of or a plurality of polypeptides shown in SEQ ID NOS: 1-7, mutants thereof, or fragments thereof in a biological sample from a subject, and to a composition for diagnosis or detection of the renal cancer.Type: ApplicationFiled: January 16, 2009Publication date: February 24, 2011Inventors: Yoshinori Tanaka, Michimoto Kobayashi, Shiori Tomoda, Giman Jung, Osamu Ogawa, Eijiro Nakamura
-
Publication number: 20110044984Abstract: The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.Type: ApplicationFiled: November 14, 2008Publication date: February 24, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takehisa Kitazawa, Tsukasa Suzuki, Shigehisa Nagahashi, Hajime Miyamoto
-
Patent number: 7892547Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: April 9, 2009Date of Patent: February 22, 2011Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 7892770Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: GrantFiled: August 24, 2007Date of Patent: February 22, 2011Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research CenterInventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
-
Patent number: 7887808Abstract: Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention further provides methods for diagnosing and treating T cell malignancies associated with abnormally truncated transcripts of human rgr oncogene and/or abnormal truncation of human Rgr protein.Type: GrantFiled: April 25, 2008Date of Patent: February 15, 2011Assignee: New York UniversityInventors: Angel Pellicer, Peter Leonardi, Giorgio Inghirami
-
Patent number: 7887806Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: GrantFiled: July 12, 2010Date of Patent: February 15, 2011Assignee: Schering CorporationInventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
-
Patent number: 7888477Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.Type: GrantFiled: June 2, 2004Date of Patent: February 15, 2011Assignee: Corixa CorporationInventors: Chaitanya S Bangur, Marc W Retter, Gary R Fanger, Paul Hill
-
Patent number: 7883702Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.Type: GrantFiled: August 25, 2005Date of Patent: February 8, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Kazunari Taira, Sunil Kaul
-
Patent number: 7875278Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.Type: GrantFiled: February 17, 2006Date of Patent: January 25, 2011Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
-
Patent number: 7871613Abstract: The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.Type: GrantFiled: August 23, 2005Date of Patent: January 18, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasuko Kinoshita, Masamichi Sugimoto, Hisafumi Okabe
-
Patent number: 7862817Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.Type: GrantFiled: January 27, 2005Date of Patent: January 4, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7863424Abstract: This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins, having the amino acid sequences set forth in any of FIG. 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2. Oligonucleotides of the isolated nucleic acid molecules are provided. Antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins are also provided, as are pharmaceutical compositions comprising such antibodies or oligonucleotides. Methods for detecting a B cell malignancy in a sample from a subject; diagnosing B cell malignancy in a sample from a subject; detecting human IRTA protein in a sample; and treating a subject having a B cell cancer are also provided.Type: GrantFiled: September 12, 2006Date of Patent: January 4, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventor: Riccardo Dalla-Favera
-
Patent number: 7855276Abstract: The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.Type: GrantFiled: December 30, 2005Date of Patent: December 21, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed Kasmiri, Rafia Mehdi Kashmiri, legal representative, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7850966Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.Type: GrantFiled: September 24, 2008Date of Patent: December 14, 2010Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
-
Patent number: 7846737Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.Type: GrantFiled: August 25, 2006Date of Patent: December 7, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Robert Schlegel, Yan Chen, Xumei Zhao, John E. Monahan, Shubhangi Kamatkar, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch
-
Patent number: 7846667Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: GrantFiled: August 20, 2009Date of Patent: December 7, 2010Assignees: Genzyme Corporation, Johns Hopkins UniversityInventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
-
Patent number: 7846673Abstract: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer.Type: GrantFiled: August 19, 2004Date of Patent: December 7, 2010Assignee: Institute of Virology of the Slovak Academy of SciencesInventors: Jaromir Pastorek, Silvia Pastorekova, Miriam Zatovicova, Jan Zavada, Marta Ortova Gut, Zuzanna Zavadova